-- 据周二在香港联交所发布的公告显示，联合实验室国际（HKG:3933）旗下珠海联合实验室已获得美国食品药品监督管理局（FDA）对其TUL321胶囊的新药申请批准。 FDA同时受理了该药物的临床试验注册申请。 该药物拟用于治疗阵发性睡眠性血红蛋白尿症（PNH）、IgA肾病、年龄相关性黄斑变性、多发性硬化症和重症肌无力。
Related Articles
International
April Dallas Fed Service Sector Index -9.9 vs. -12 Expected, Prior -13.3 Reading
Australia
RTX's Raytheon Delivers Second Satellite Sensor to Lockheed Martin Under US Space Force Program
RTX-owned (RTX) Raytheon said Tuesday it has delivered its second sensor to Lockheed Martin (LMT) for the US Space Force's satellite program.The satellites, which are part of the Next-Generation Overhead Persistent Infrared Geosynchronous Earth Orbit Block 0 satellite program, will provide enhanced missile warning and tracking to deal with space-based threats, Raytheon said.Financial terms of the contract were not disclosed.Price: $173.20, Change: $-0.18, Percent Change: -0.10%
$LMT$RTX
Equities
BP Says Focused on Delivering 'Stronger' Balance Sheet Amid Q1 Profit Surge
BP (BP.L) is focused on rebuilding its balance sheet rather than reinstating share buybacks, even as its first-quarter profit surged amid the Middle East conflict, Bloomberg News reported Tuesday.In a phone interview, Chief Financial Officer Kate Thomson, alongside new Chief Executive Officer Meg O'Neill, said the British energy major is "completely focused right now on delivering a stronger balance sheet," adding that it will cut debt and perpetual hybrid bonds to improve its financial position.Thomson noted that share repurchases "ultimately will remain a tool as and when appropriate."
$BP.L